The following is a summary of the Avid Bioservices, Inc. (CDMO) Q3 2024 Earnings Call Transcript:

Financial Performance:

• Avid Bioservices saw a significant increase in revenues by over 30% in Q3 2024 compared to Q2 2024, culminating in earnings of $33.8 million.

• Gross margin for Q3 was relatively low at 7% compared to 26% in Q3 2023.

• The net loss for Q3 2024 was $6 million, considerably higher than the $0.2 million of the same period the previous year.

• The company maintained cash and cash equivalents of $30.7 million as of January 31, 2024.

Business Progress:

• Business growth was supported by new project agreements, resulting in a backlog of over $200 million.

• The Q3 2024 saw the successful opening of their cell and gene therapy facility and completion of the three-year expansion program.

• The company refinance of convertible notes extended the debt maturity to 2029, improving its financial flexibility.

• With the operational CGT facility, Avid is now able to engage customers with a complete product offering, expected to improve cash flow and margins.

• An increase in early-stage project bookings indicates an improving financing environment for biotechs.

• Future capital expenditure is planned for maintenance and software, following the completion of the current expansion.

• The company looks forward to closing the fiscal year with a CapEx of around $32 million.

More details: Avid Bioservices IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.